Ali Rossiter lands new appointment

Former Novartis ANZ Country President, Allison Rossiter, has joined Clarity Pharmaceuticals’ Board of Directors, revealing why the prostate cancer-focused company’s work is “personally significant”.

Rossiter’s new role as independent Non-Executive Director for the ASX-listed clinical stage radiopharmaceutical company comes exactly a month since she resigned from Novartis after three months in the top job, for personal reasons.

“Clarity is entering a pivotal phase in its evolution - progressing from proprietary innovation at the bench to the cusp of commercialisation in a significant global market,” Rossiter said.